• Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumabHagström, Emil; Steg, P. Gabriel; Szarek, Michael; Bhatt, Deepak L.; Bittner, Vera A.; Danchin, Nicolas; Diaz, Rafael; Goodman, Shaun G.; Harrington, Robert A.; Jukema, J. Wouter; Liberopoulos, Evangelos; Marx, Nikolaus; Viigimaa, MargusCirculation2022 / p. 657 - 672 https://doi.org/10.1161/CIRCULATIONAHA.121.057807 https://www.scopus.com/sourceid/22581 https://www.scopus.com/record/display.uri?eid=2-s2.0-85137105629&origin=resultslist&sort=plf-f&src=s&sid=de91c20ae4aba03588cc8b0e4d3de083&sot=b&sdt=b&s=AUTHOR-NAME%28viigimaa%29&sl=21&sessionSearchId=de91c20ae4aba03588cc8b0e4d3de083 https://jcr.clarivate.com/jcr-jp/journal-profile?journal=CIRCULATION&year=2022 https://www.webofscience.com/wos/woscc/full-record/WOS:000844880000004
• Effects of alirocumab on cardiovascular events after coronary bypass surgeryGoodman, Shaun G.; Aylward, Philip E.; Szarek, Michael; Viigimaa, MargusJournal of the American College of Cardiology2019 / p. 1177−1186 : ill https://doi.org/10.1016/j.jacc.2019.07.015
• Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterolSchwartz, Gregory G.; Szarek, Michael; Bittner, Vera A.; Diaz, Rafael; Goodman, Shaun G.; Viigimaa, MargusJournal of the American College of Cardiology2021 / p. 421–433 : ill https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102 https://doi.org/10.1016/j.jacc.2021.04.102